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randomized controlled clinical trials (RCTs) occupy a pivotal position in assessing the effectiveness of treatments 
for skin disease. The rudiments of the experi-
mental design allow for control of selection, 
performance, detection, and attrition bias, and 
prospective trial registration offers further pro-
tection against selective reporting outcome bias 
and publication bias (Williams and Dellavalle, 
2012). Clinical trials are the backbone of 
systematic reviews of clinical interventions, 
treatment guidelines, and drug licensing 
submissions. Cost-effectiveness studies in 
relation to RCTs are also essential for informing 
commissioning decisions in countries with state-
funded health care, such as those undertaken by 
the UK National Institute of Health and Clinical 
Excellence. Despite their potential in reduc-
ing treatment uncertainties in dermatology, the 
usefulness of RCTs is limited by two factors: 
(i) the quality of design and reporting and (ii) the 
clinical question that the trials address.
Although there are some sparkling diamonds 
(Green et al., 1999; Joly et al., 2009), clinical 
trials in dermatology are often too small, poor-
ly designed, and too poorly reported to reduce 
treatment uncertainties (Nankervis et al., 2012). 
The problem of poor trial reporting is poten-
tially easy to fix by requiring all trials to report 
the essential trial features as specified in the 
CONSORT-2010 statement (http://www.consort-
statement.org), as is the policy of the Journal 
of Investigative Dermatology (Williams and 
Goldsmith, 2006). Selective reporting outcome 
bias (choosing which results of many to high-
light once the study has been analyzed) can be 
overcome by prospectively registering all RCTs 
in a publicly accessible database before recruit-
ment starts (Chan et al., 2004). Small trials are 
trickier to address. Time and time again, when 
systematic reviews of skin disease treatments 
are prepared by the Cochrane Collaboration, 
the same predictable results emerge—around 30 
underpowered and highly heterogeneous RCTs, 
most of which are at high risk of bias because 
of unclear description of key elements such as 
randomization, blinding, and loss to follow-up 
(Whitton et al., 2010; van Zuuren et al., 2011). 
Typically, these reviews end up with that frus-
trating conclusion “insufficient evidence” or 
that vacuous phrase “more research is needed,” 
which, although true, is of little use to clinicians. 
More research of the same type is not needed—
what is needed is less but better research in the 
sense that the proposed RCT will answer a key 
dilemma in dermatological clinical practice, 
is large enough to answer the questions posed, 
and is reported clearly enough to allow the read-
er to decide whether the trial was a good one 
(Williams, 2011).
Improving study design and reporting can be 
overcome to some extent by these measures, but 
how can the clinical trials agenda for dermatol-
ogy better reflect clinical priorities? It is no use 
relying on the drug industry to produce a com-
prehensive plan to solving all treatment dilem-
mas in dermatology (Naldi et al., 2010). The 
drug industry has its own agenda of trying to 
produce new, effective, and safe treatments that 
will also result in financial return. There is noth-
ing wrong with that, apart from the fact that, like 
any other business, the industry agenda is guid-
ed by the need to offer something that is better 
than existing treatment in diseases that are com-
mon enough to ensure returns on investment. It 
is also worth noting that trials run by industry 
are generally well designed and well report-
ed (Thomas et al., 2008) and are a standard to 
which independent research should aspire. 
Industry cannot be relied on to answer key ques-
tions in dermatology such as “How does this 
new treatment compare to existing treatments?” 
as opposed to “Does this treatment work when 
compared with placebo and is it reasonably safe 
in the short-term?” A paucity of comparative-
effectiveness research (according to the Agency 
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for Healthcare Research and Quality, http://www.effective-
healthcare.ahrq.gov/index.cfm/what-is-comparative-effec-
tiveness-research1) has meant that the market has become 
flooded with more and more products, some of which offer 
genuine choice, but many of which are simply “me too” 
products of dubious advantage. In the UK, for example, we 
have over 20 different topical preparations for acne based on 
just five main ingredients (Joint Formulary Committee, British 
National Formulary, http://www.bnf.org/bnf/index.htm). 
How can any doctor decide which is best unless they have 
been tested against each other on a level playing field? Such 
comparative-effectiveness studies are rare, but when they 
are done, they can produce some surprises; for example, a 
study comparing five different acne regimens for mild facial 
acne in the community found that old-fashioned and cheap 
5% benzoyl peroxide was just as effective as and had fewer 
adverse effects than oral minocycline (Ozolins et al., 2004). 
Another study of systemic therapies or phototherapy for 
psoriasis has shown that effectiveness in a real-world clinic 
setting is lower than that reported in previous trials (Gelfand 
et al., 2012). The lack of symmetry in the tree of dermatology 
clinical trials research (Figure 1) also percolates through to 
evidence-based guidelines. Those producing them often find 
themselves in a dilemma of strongly recommending expen-
sive new products developed by industry because they have 
passed the “RCTs level of evidence” test, at the expense of 
older but very-well-established products (Gilchrest and 
Martin, 2012), a mismatch I call the inverse research law—
where the need for evidence is greatest, the quality and 
quantity of evidence are least.
In addition to addressing comparative-effectiveness 
research for common skin problems, the second challenge 
for the dermatology clinical trials agenda is how to address 
the many questions that need answering about less common 
skin diseases such as pyoderma gangrenosum (Craig et al., 
2012) or questions that address the use of established cheaper 
treatments such as oral tetracyclines for bullous pemphigoid 
(Bratton et al., 2012)—questions that are of high interest to 
the global clinical community but offer poor returns for indus-
try. The same applies to nonpharmacological interventions 
such as water softeners or specialized clothing or bandages 
for atopic dermatitis or gloves for prevention of occupation-
al hand dermatitis (Thomas et al., 2011; Bauer et al., 2010). 
Independent government and charity funding is needed to 
address such real-world comparative-effectiveness studies. 
Such sources do exist, but tapping into them is highly compet-
itive—only applications of the highest perceived priority and 
quality are funded and only those that are supported by the 
right methodological and trial management expertise.
One way forward to tackle the many important questions 
that need addressing in clinical practice is to form a network 
of like-minded people. Such networks can be disease spe-
cific, for example, for autoimmune blistering diseases (Meyer 
et al., 2011), or country-specific, as in the case of the UK 
Dermatology Clinical Trials Network (UK DCTN (http://www.
ukdctn.org); Layfield et al., 2011). The main function of the 
UK DCTN, which has been running for 10 years, is to iden-
tify and prioritize research questions and then to develop these 
questions into fundable proposals by undertaking feasibility 
studies and working with patients and clinical trial method-
ologists. Currently, the UK DCTN is running four national tri-
als and has succeeded in competing for funds against the top 
medical and surgical specialties. In addition to developing and 
running clinical trials proposed by its membership, the network 
has also fulfilled a key educational role in bringing on train-
ees. Such trainees learn about topic prioritization exercises that 
are held between professionals and patients, trial development 
and funding application processes, and, later, the manage-
ment and successful delivery of funded trials. But perhaps the 
greatest value of such a network is the way in which it engages 
the clinical dermatology community. Previous dermatologi-
cal clinical trials have largely been the domain of academ-
ics—and rightly so because research is what academics do. Yet 
many busy clinicians also yearn to participate in, rather than 
lead, clinical research—clinicians who might have done sub-
stantial research during their training, but who now find them-
selves overwhelmed by clinical practice. Networks such as 
the UK DCTN have tapped into the enthusiasm of such clini-
cians in a way that has enabled much wider engagement with 
identifying and reducing clinical uncertainties in what may be 
described as a “democratization of clinical research” (Lloyd 
and White, 2011). Clinicians are often in the best position to 
suggest important questions for investigator-initiated research. 
Indeed, it was such a clinician—the late Neil Cox—who sug-
gested the first two UK DCTN trials on prevention of cellulitis 
relapses with oral penicillin, the results of which are now deliv-
ering benefit back in the clinic (Thomas et al., 2012). The UK 
has also been fortunate in recent years to have the benefit of an 
integrated network of research nurses funded by the National 
Institute for Health Research Comprehensive Clinical Research 
Network (http://www.crncc.nihr.ac.uk/about_us/ccrn/specialty/
dermatology) who are dedicated to recruiting into national 
portfolio studies, thereby helping with study delivery.
This example of the UK DCTN is not intended to serve as a 
blueprint for all countries to follow, but is an example of what 
is possible when the clinical and research communities col-
laborate across many centers to compete for national fund-
ing against other medical specialties. Skin disease has many 
trump cards to play when making the case for funding, such as 
Figure 1. investigator-led comparative-effectiveness research questions. 
Such questions are still twigs in the overall agenda depicted in the tree of 
dermatologic clinical trials.
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high prevalence or large impacts on quality of life (Schofield 
et al., 2009). Administrative hurdles for approvals within and 
across countries can be extremely challenging, but they can 
be overcome and are easier to manage with dedicated core 
staff. There is a real opportunity for other countries and groups 
to organize themselves into professional networks that work to 
industry standards and are able to tap into what limited funds 
are available (Sivanandam et al., 2010). There is great poten-
tial for international collaboration in such an endeavor. To 
this end, the International Federation of Dermatology Clinical 
Trial Networks (http://www.ifdctn.org) has been set up to share 
good practices. Trial protocols can be shared so that robust 
designs can be adapted when evaluating similar questions 
in different populations emanating from different countries. 
Other countries may choose to evaluate the same drugs in dif-
ferent populations or use different standard comparators based 
on availability and local priorities. Research wastage could be 
reduced by minimizing unplanned duplication of trials. Such 
a federation will also encourage the use of the same outcome 
sets (Schmitt et al., 2011) for particular diseases to facilitate 
future network meta-analysis and comparisons in systematic 
reviews and guidelines. The ultimate potential for such an 
international federation is to work together on reducing uncer-
tainties for rare skin diseases, such as looking at the possible 
benefits and harms of immunoglobulin for toxic epidermal 
necrolysis (Walsh and Creamer, 2012).
There has never been a more exciting time for comparative-
effectiveness research in dermatology, but progress can be 
achieved only by teaming up with methodologists and by work-
ing together within and across countries. Some organizations, 
such as the American Dermato-Epidemiology Network (http://
www.adenet.us/DECTRC.html), have already made a start in 
the right direction. The Journal of Investigative Dermatology is 
proud to be part of this journey of global unity in improving the 
relevance and quality of dermatology clinical trials and wel-
comes high-quality clinical trial submissions that will make a 
difference in the lives of our patients.
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